223 related articles for article (PubMed ID: 19965597)
1. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.
Briand F; Tréguier M; André A; Grillot D; Issandou M; Ouguerram K; Sulpice T
J Lipid Res; 2010 Apr; 51(4):763-70. PubMed ID: 19965597
[TBL] [Abstract][Full Text] [Related]
2. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
3. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
Briand F; Thieblemont Q; Muzotte E; Sulpice T
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):13-23. PubMed ID: 23139291
[TBL] [Abstract][Full Text] [Related]
4. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo.
Yasuda T; Grillot D; Billheimer JT; Briand F; Delerive P; Huet S; Rader DJ
Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):781-6. PubMed ID: 20110577
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.
Naik SU; Wang X; Da Silva JS; Jaye M; Macphee CH; Reilly MP; Billheimer JT; Rothblat GH; Rader DJ
Circulation; 2006 Jan; 113(1):90-7. PubMed ID: 16365197
[TBL] [Abstract][Full Text] [Related]
6. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.
Castro-Perez J; Briand F; Gagen K; Wang SP; Chen Y; McLaren DG; Shah V; Vreeken RJ; Hankemeier T; Sulpice T; Roddy TP; Hubbard BK; Johns DG
J Lipid Res; 2011 Nov; 52(11):1965-73. PubMed ID: 21841206
[TBL] [Abstract][Full Text] [Related]
7. High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters.
Briand F; Thiéblemont Q; Muzotte E; Sulpice T
J Nutr; 2012 Apr; 142(4):704-9. PubMed ID: 22357742
[TBL] [Abstract][Full Text] [Related]
8. LXR driven induction of HDL-cholesterol is independent of intestinal cholesterol absorption and ABCA1 protein expression.
Kannisto K; Gåfvels M; Jiang ZY; Slätis K; Hu X; Jorns C; Steffensen KR; Eggertsen G
Lipids; 2014 Jan; 49(1):71-83. PubMed ID: 24163219
[TBL] [Abstract][Full Text] [Related]
9. Diet-induced dyslipidemia impairs reverse cholesterol transport in hamsters.
Tréguier M; Briand F; Boubacar A; André A; Magot T; Nguyen P; Krempf M; Sulpice T; Ouguerram K
Eur J Clin Invest; 2011 Sep; 41(9):921-8. PubMed ID: 21299553
[TBL] [Abstract][Full Text] [Related]
10. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice.
Nijstad N; Gautier T; Briand F; Rader DJ; Tietge UJ
Gastroenterology; 2011 Mar; 140(3):1043-51. PubMed ID: 21134376
[TBL] [Abstract][Full Text] [Related]
11. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.
Breevoort SR; Angdisen J; Schulman IG
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1650-60. PubMed ID: 24947527
[TBL] [Abstract][Full Text] [Related]
12. Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8.
Calpe-Berdiel L; Rotllan N; Fiévet C; Roig R; Blanco-Vaca F; Escolà-Gil JC
J Lipid Res; 2008 Sep; 49(9):1904-11. PubMed ID: 18509196
[TBL] [Abstract][Full Text] [Related]
13. Xanthohumol, a hop-derived prenylated flavonoid, promotes macrophage reverse cholesterol transport.
Hirata H; Uto-Kondo H; Ogura M; Ayaori M; Shiotani K; Ota A; Tsuchiya Y; Ikewaki K
J Nutr Biochem; 2017 Sep; 47():29-34. PubMed ID: 28501703
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe Enhances Macrophage-to-Feces Reverse Cholesterol Transport in Golden Syrian Hamsters Fed a High-Cholesterol Diet.
Kasbi Chadli F; Treguier M; Briand F; Sulpice T; Ouguerram K
J Pharmacol Exp Ther; 2020 Oct; 375(2):349-356. PubMed ID: 32873624
[TBL] [Abstract][Full Text] [Related]
15. Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents.
Shinozawa E; Amano Y; Yamakawa H; Haba M; Shimada M; Tozawa R
Pharmacol Res Perspect; 2018 Apr; 6(2):e00390. PubMed ID: 29541476
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol administration or SIRT1 overexpression does not increase LXR signaling and macrophage-to-feces reverse cholesterol transport in vivo.
Escolà-Gil JC; Julve J; Llaverias G; Urpi-Sarda M; Silvennoinen R; Lee-Rueckert M; Andres-Lacueva C; Blanco-Vaca F
Transl Res; 2013 Feb; 161(2):110-7. PubMed ID: 23146569
[TBL] [Abstract][Full Text] [Related]
17. Synthetic LXR agonists increase LDL in CETP species.
Groot PH; Pearce NJ; Yates JW; Stocker C; Sauermelch C; Doe CP; Willette RN; Olzinski A; Peters T; d'Epagnier D; Morasco KO; Krawiec JA; Webb CL; Aravindhan K; Jucker B; Burgert M; Ma C; Marino JP; Collins JL; Macphee CH; Thompson SK; Jaye M
J Lipid Res; 2005 Oct; 46(10):2182-91. PubMed ID: 16024916
[TBL] [Abstract][Full Text] [Related]
18. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol.
Briand F; Naik SU; Fuki I; Millar JS; Macphee C; Walker M; Billheimer J; Rothblat G; Rader DJ
Clin Transl Sci; 2009 Apr; 2(2):127-33. PubMed ID: 20169010
[TBL] [Abstract][Full Text] [Related]
19. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
van der Hoorn J; Lindén D; Lindahl U; Bekkers M; Voskuilen M; Nilsson R; Oscarsson J; Lindstedt E; Princen H
Br J Pharmacol; 2011 Apr; 162(7):1553-63. PubMed ID: 21175581
[TBL] [Abstract][Full Text] [Related]
20. The use of dyslipidemic hamsters to evaluate drug-induced alterations in reverse cholesterol transport.
Briand F
Curr Opin Investig Drugs; 2010 Mar; 11(3):289-97. PubMed ID: 20178042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
